Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 81

1.

HER2 in well differentiated breast cancer: is testing necessary?

Haines GK 3rd, Wiley E, Susnik B, Apple SK, Frkovic-Grazio S, Reyes C, Goldstein LC, Dadmanesh F, Gown AM, Nadji M, Bracko M, Tavassoli FA.

Breast Cancer Res Treat. 2008 Dec;112(3):551-6. doi: 10.1007/s10549-008-9893-8. Epub 2008 Jan 18.

PMID:
18202913
2.

HER2 testing in breast cancer: NCCN Task Force report and recommendations.

Carlson RW, Moench SJ, Hammond ME, Perez EA, Burstein HJ, Allred DC, Vogel CL, Goldstein LJ, Somlo G, Gradishar WJ, Hudis CA, Jahanzeb M, Stark A, Wolff AC, Press MF, Winer EP, Paik S, Ljung BM; NCCN HER2 Testing in Breast Cancer Task Force.

J Natl Compr Canc Netw. 2006 Jul;4 Suppl 3:S1-22; quiz S23-4. Review.

PMID:
16813731
3.

Quantitative HER2 protein levels predict outcome in fluorescence in situ hybridization-positive patients with metastatic breast cancer treated with trastuzumab.

Lipton A, Köstler WJ, Leitzel K, Ali SM, Sperinde J, Weidler J, Paquet A, Sherwood T, Huang W, Bates M; Trastuzumab Response Biomarker Group.

Cancer. 2010 Nov 15;116(22):5168-78. doi: 10.1002/cncr.25430.

4.

HER2 testing in gastric cancer.

Albarello L, Pecciarini L, Doglioni C.

Adv Anat Pathol. 2011 Jan;18(1):53-9. doi: 10.1097/PAP.0b013e3182026d72. Review.

PMID:
21169738
5.
6.

Standardization of HER2 testing: results of an international proficiency-testing ring study.

Dowsett M, Hanna WM, Kockx M, Penault-Llorca F, Rüschoff J, Gutjahr T, Habben K, van de Vijver MJ.

Mod Pathol. 2007 May;20(5):584-91. Epub 2007 Mar 30.

7.

Concordance between central and local laboratory HER2 testing from a community-based clinical study.

Reddy JC, Reimann JD, Anderson SM, Klein PM.

Clin Breast Cancer. 2006 Jun;7(2):153-7.

PMID:
16800975
8.

HER2 testing on core needle biopsy specimens from primary breast cancers: interobserver reproducibility and concordance with surgically resected specimens.

Tsuda H, Kurosumi M, Umemura S, Yamamoto S, Kobayashi T, Osamura RY.

BMC Cancer. 2010 Oct 7;10:534. doi: 10.1186/1471-2407-10-534.

9.

EGFR over-expression and activation in high HER2, ER negative breast cancer cell line induces trastuzumab resistance.

Dua R, Zhang J, Nhonthachit P, Penuel E, Petropoulos C, Parry G.

Breast Cancer Res Treat. 2010 Aug;122(3):685-97. doi: 10.1007/s10549-009-0592-x. Epub 2009 Oct 27.

PMID:
19859802
10.

[Human recombinant anti-HER2 monoclonal antibody--a new targeted treatment in breast cancer].

Dank M.

Orv Hetil. 2001 Nov 18;142(46):2563-8. Review. Hungarian.

PMID:
11770175
11.

HER2 testing in a population-based study of patients with metastatic breast cancer treated with trastuzumab.

O'Malley FP, Thomson T, Julian J, Have C, Cosby R, Gelmon K, Andrulis I, Whelan T.

Arch Pathol Lab Med. 2008 Jan;132(1):61-5. doi: 10.1043/1543-2165(2008)132[61:HTIAPS]2.0.CO;2. Erratum in: Arch Pathol Lab Med.2008 May;132(5):730. Crosby, Roxanne [corrected to Cosby, Roxanne].

PMID:
18181675
12.

Breast cancer HER2 equivocal cases: is there an alternative to FISH testing? A pilot study using two different antibodies sequentially.

Yosepovich A, Avivi C, Bar J, Polak-Charcon S, Mardoukh C, Barshack I.

Isr Med Assoc J. 2010 Jun;12(6):353-6.

13.
14.

Prognostic utility of fluorescence in situ hybridization for determining HER2 gene amplification in breast cancer.

Kammori M, Kurabayashi R, Kashio M, Sakamoto A, Yoshimoto M, Amano S, Kaminishi M, Yamada T, Takubo K.

Oncol Rep. 2008 Mar;19(3):651-6.

PMID:
18288397
15.

Polysomy 17 in breast cancer: clinicopathologic significance and impact on HER-2 testing.

Vanden Bempt I, Van Loo P, Drijkoningen M, Neven P, Smeets A, Christiaens MR, Paridaens R, De Wolf-Peeters C.

J Clin Oncol. 2008 Oct 20;26(30):4869-74. doi: 10.1200/JCO.2007.13.4296. Epub 2008 Sep 15.

PMID:
18794552
16.

Triple-negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy: a translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III trial.

Skarlos P, Christodoulou C, Kalogeras KT, Eleftheraki AG, Bobos M, Batistatou A, Valavanis C, Tzaida O, Timotheadou E, Kronenwett R, Wirtz RM, Kostopoulos I, Televantou D, Koutselini E, Papaspirou I, Papadimitriou CA, Pectasides D, Gogas H, Aravantinos G, Pavlidis N, Arapantoni P, Skarlos DV, Fountzilas G.

Cancer Chemother Pharmacol. 2012 Feb;69(2):533-46. doi: 10.1007/s00280-011-1730-9. Epub 2011 Sep 8.

PMID:
21901395
17.

Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm.

Burstein HJ, Harris LN, Marcom PK, Lambert-Falls R, Havlin K, Overmoyer B, Friedlander RJ Jr, Gargiulo J, Strenger R, Vogel CL, Ryan PD, Ellis MJ, Nunes RA, Bunnell CA, Campos SM, Hallor M, Gelman R, Winer EP.

J Clin Oncol. 2003 Aug 1;21(15):2889-95.

PMID:
12885806
18.

Human epidermal growth factor receptor 2 testing in gastroesophageal cancer: correlation between immunohistochemistry and fluorescence in situ hybridization.

Tafe LJ, Janjigian YY, Zaidinski M, Hedvat CV, Hameed MR, Tang LH, Hicks JB, Shah MA, Barbashina V.

Arch Pathol Lab Med. 2011 Nov;135(11):1460-5. doi: 10.5858/arpa.2010-0541-OA.

PMID:
22032573
19.

Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients.

Dressler LG, Berry DA, Broadwater G, Cowan D, Cox K, Griffin S, Miller A, Tse J, Novotny D, Persons DL, Barcos M, Henderson IC, Liu ET, Thor A, Budman D, Muss H, Norton L, Hayes DF.

J Clin Oncol. 2005 Jul 1;23(19):4287-97.

PMID:
15994142
20.

Current issues in ER and HER2 testing by IHC in breast cancer.

Gown AM.

Mod Pathol. 2008 May;21 Suppl 2:S8-S15. doi: 10.1038/modpathol.2008.34. Review.

Supplemental Content

Support Center